Slides
Page 1
ScopeGuide FIE Consolidated Financial Results for the 1st Quarter of Fiscal Year 2027 August 7 , 2026 Olympus Corporation | Director , Representative Executive Officer , President and Chief Executive Officer , Bob White | Executive Officer and Chief Financial Officer , Michael Parenti OLYMPUS
Page 2
▪ This material contains forward-looking statements that reflect management’s current views, plans, and expectations based on information available at the time of preparation. These forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, future business decisions, and other internal and external factors that may cause the Company’s actual results, performance, achievements, or financial position to be materially different from any future results expressed or implied by these forward-looking statements. ▪ Additionally, this information is subject to change without notice. Accordingly, other information should be used in addition to this material when making investment decisions. ▪ This material is not intended for promotional or medical advice use. Products or devices presented include future technology which may be pending regional regulatory approval and are not available for sale in all regions. It is provided to give examples of technology development by Olympus and no guarantees are made about the future sale of such products. ▪ Olympus Corporation assumes no responsibility for any damage resulting from the use of this material. Disclaimer 2
Page 3
3 Table of Contents 1. Executive Summary 2. Strategic Progress 3. Q1 Fiscal Year 2027 Financial Results and Business Review 4. Progress Against Full-Year Guidance 5. Appendix CEO CFO CEO Executive Summary Table of contents Strategic Progress Financial Results Appendix CFO Consolidated Guidance
Page 4
Executive Summary 4 Executive Summary Table of contents Strategic Progress Financial Results AppendixConsolidated Guidance
Page 5
Where Purpose Meets Performance: Shaping the Future of Endoscopy-Enabled Care 5 Executive Summary Table of contents Strategic Progress Financial Results AppendixConsolidated Guidance Making people’s lives healthier , safer and more fulfilling OUR PURPOSE OUR FINANCIAL ASPIRATIONS FY27-29 100+ bps Year-on-year growth from FY26 Op Margin2 3-4-5 % Growing at 5% by FY29 Revenue1 >10 % From FY26 EPS CAGR2 OUR STRATEGIC PILLARS Innovation-Driven Growth Lead the next wave of innovation & expand to faster-growing segments Simplicity Simplify Olympus to move faster and operate smarter Accountability Support a high-performance culture of quality, ownership and execution 1 Constant Currency basis 2 Adjusted for extraordinary items: Exclude “Other income/expenses, no adjustment will be made for the impact of exchange rate fluctuations, actual exchange rate will be used
Page 6
Strategic Progress 6 Executive Summary Table of contents Strategic Progress Financial Results AppendixConsolidated Guidance
Page 7
Progress Against Our Strategic Pillars 7 Executive Summary Table of contents Strategic Progress Financial Results AppendixConsolidated Guidance Accountability Support a high-performance culture of quality, ownership and execution ▪ Achieved strong growth in Q1, driven by robust GIS performance in North America, Europe, and APAC ▪ Driving consistent drumbeat of execution through stronger accountability and performance metrics ▪ Surgical review remains ongoing Innovation-Driven Growth Lead the next wave of innovation & expand to faster-growing segments ▪ The momentum of the EVIS X1 platform, especially EDOF scope, continues ▪ [30+] 510(k) clearances received from the FDA in the past 12 months ▪ BioProtect acquisition closed: entry into prostate cancer care Simplicity Simplify Olympus to move faster and operate smarter ▪ The Division-led operating model sets the foundation to drive efficiency in the long term ▪ Almost completed position optimization ▪ Steadily progressing toward the plan, on pace to achieve ¥24B in annualized savings by FY28
Page 8
8 FY2027 is Off to a Good Start 1 Year-on-Year 2 Constant Currency (After FX adjustment) GIS remains growth engine ¥168.4B Revenue +21% YoY1 +10% CC2 SIS headwind islimited ¥71.9B Revenue +7% YoY1 -4% CC2 Revenue impact remains concentrated in specific ship-hold- affected products Ship-hold headwind is known and defined with a visible path to normalization The core franchises (Urology and Respiratory) are healthy and growing YoY1,2 Consolidated revenue: ¥240.4B, +16% YoY1, +5% CC2 – driven by robust GIS performance in North America, Europe, and APAC Full-year guidance maintained on strength of Q1 performance Margin expansion was supported by revenue growth, R&D expenditure timing, and personnel expense savings from the position optimization program We're reaffirming our full-year guidance. Structural tailwinds expected in H2 will help drive growth and deliver our FY commitments Executive Summary Table of contents Strategic Progress Financial Results AppendixConsolidated Guidance Double-digit growth1,2 across North America, Europe, and APAC confirms GIS as Olympus' growth engine Growth was supported by strong demand across the GI portfolio Sustained strength in North America and Europe demonstrates healthy underlying demand and disciplined commercial execution
Page 9
Sustained Growth Across Core Markets 9 North America, Europe, and APAC ▪ Delivered a second consecutive quarter of double-digit growth1,2 in GIS, demonstrating sustained momentum across our core markets. ▪ GIS growth was led by continued adoption of EDOF scopes and strong demand for GI EndoTherapy devices ▪ Improved commercial execution and product availability are translating healthy pipelines into sales ▪ Strong customer demand supports continued growth, although YoY comparisons become more demanding after Q1 in GIS China and Japan ~20% of sales China (–3% YoY1) ▪ Lower-GI EDOF launch expanded localized portfolio in Q1 ▪ GIS performance broadly in line with expectations despite continued market pressure ▪ Gradual H2 improvement expected as localization gains traction Japan (0% YoY1) ▪ Stable performance supported by key GI scope products ▪ Focused commercial execution to drive improved performance -8% CC2 ~80% of sales +9% CC2 +21% YoY1 -1% YoY1 1 Year-on-Year 2 Constant Currency (After FX adjustment) Executive Summary Table of contents Strategic Progress Financial Results AppendixConsolidated Guidance
Page 10
10 Patient Safety Remains Our Unconditional Focus Executive Summary Table of contents Strategic Progress Financial Results AppendixConsolidated Guidance Majority of ship-hold-affected products expected to return to market in H2 FY27 Quality Leadership FDA Engagement Business Continuity Appointed Brian Barry, 40+ year industry veteran as Executive Officer and Chief Quality Officer. Brian will lead our next phase of quality enhancement continuing to sharpen our systems and advancing our culture Continuous, constructive engagement with FDA maintained. Olympus remains committed to full transparency with the agency as work progresses
Page 11
Technology in Action: Delivering Innovation That Advances Care Executive Summary Table of contents Strategic Progress Financial Results AppendixConsolidated Guidance 11 FY26 FY27 FY28 3% 5% Potential growth upside through M&A, etc. 4% Key Drivers1 [30+] 510(k) clearances received from the FDA in the past 12 months EVIS X1 Scopes CNUS EU CNUS JP APAC GI OLYSENSE APACEUUS EUUS GI Aplio i800 US GI APACEU VIABIL US GI-ET Single-use Ureteroscope & Cystoscope EUUS APAC JP URO Single-use Bronchoscope EU RESP Peripheral EBUS APACJPEU US CN RESP 1 Assumptions as of August 7, 2026. Product launch timing is subject to change. FY29 Laser System US EU URO EU-ME3 CNUS GI/RESP Launched in FY26 / Planned launches from FY27 onwards Retentia APACEU GI-ET CN EUS Scope APACEU JPUS GI Single-use Duodenoscope US JP APAC GI EU SecureFlex GI-ET EUUS APACJP CN
Page 12
12 Consolidated Financial Results and Business Review FY2027 Q1 Executive Summary Table of contents Strategic Progress Financial Results AppendixConsolidated Guidance
Page 13
13 Fiscal Year 2027 Q1 Highlights ▪ Adjusted operating margin1 of 12.8%, up 6.4pp YoY (+5.7pp CC), supported by revenue growth, lower R&D, and personnel expenses ¥240.4B Highlights Q1 results marked a good start, reinforcing confidence in achieving full-year guidance 1 The amount after deducting “Other income” and “Other expenses” from operating profit. 2 Year-on-Year 3 Constant Currency (After FX adjustment) Revenue Executive Summary Table of contents Strategic Progress Financial Results AppendixConsolidated Guidance ▪ Revenue of ¥240.4B, up 16% (+5% CC), driven by strong GIS performance across North America, Europe and APAC 12.8%Adjusted OPM1 ¥20 Adjusted EPS ¥9.2BAdjusted FCF +16% YoY2 +5% CC3 +6.4pp YoY2 +5.7pp CC3 +130% YoY2 +¥26.7B YoY2
Page 14
14 Fiscal Year 2027 Q1 Gastrointestinal Solutions Division Executive Summary Table of contents Strategic Progress Financial Results AppendixConsolidated Guidance 1 Approx. 2 Year-on-Year 3 Constant Currency (After FX adjustment) Revenue ¥168.4B GI Endoscopy +24% YoY2 +12% CC3 +21% YoY2 +10 ％ CC3 Key Factors for Q1 Results (YoY) GI Endoscopy Revenue grew 24% year-on-year, led by continued EDOF scope adoption and strong EU-ME3 demand. Growth was broad-based, with double-digit performance across North America, Europe, and APAC. GI EndoTherapy Revenue grew 28% year-on-year, driven by strong VIABIL performance and continued growth across the core portfolio. North America and Europe led the increase. Medical Service Revenue grew 15% year-on-year, supported by recurring service contract revenue and solid execution in Europe and North America. GI EndoTherapy +28% YoY2 +16% CC3 Medical Service +15% YoY2 +4% CC3 45%1 20%1 35%1
Page 15
15 Fiscal Year 2027 Q1 Surgical and Interventional Solutions Division Executive Summary Table of contents Strategic Progress Financial Results AppendixConsolidated Guidance Key Factors for Q1 Results (YoY) Urology Urology delivered 14% year-on-year growth mainly driven by resection electrodes for BPH. Growth was led by Europe and North America. Respiratory Respiratory delivered 15% year-on-year growth driven by EBUS scopes and needles. Growth was led by North America. Surgical Endoscopy Surgical Endoscopy delivered 9% year-on-year growth, led by strong performance in Europe and favorable FX. Other Therapeutic Areas Revenue decreased by 17% year-on-year mainly due to ship-holds for certain products in surgical devices. Urology +14% YoY2 +2% CC3 +7% YoY2 -4 ％ CC3 Surgical Endoscopy +9% YoY2 -2% CC3 Other Therapeutic Areas -17% YoY2 -24% CC3 45%1 20%1 20%1 15%1 Respiratory +15% YoY2 +4% CC3 Revenue ¥71.9B 1 Approx. 2 Year-on-Year 3 Constant Currency (After FX adjustment)
Page 16
16 Progress Against Full-Year Guidance FY2027 Executive Summary Table of contents Strategic Progress Financial Results AppendixConsolidated Guidance
Page 17
+4.4% YoY3 +6.5% YoY3 17 Fiscal Year 2027 Consolidated Guidance Revenue ¥1,055.0B ¥1,076.0B +1.5% CC2 +3.5% CC2 15.2% 16.7% +1.0pp YoY3 +2.5pp YoY3 ¥106 ¥119Adjusted EPS +15% YoY3 +29% YoY3 1 The amount after deducting “Other income” and “Other expenses” from operating profit. 2 Constant Currency (After FX adjustment) 3 Year-on-Year Adjusted OPM1 FY27 Guidance ▪Full-year guidance unchanged from May ▪100+ bps of annual margin improvement is on track Q1 performance reflects a solid start to the year . This reinforces our conviction in our plan and supports our confidence in delivering on our FY27 commitments. Executive Summary Table of contents Strategic Progress Financial Results AppendixConsolidated Guidance
Page 19
19 Appendix Executive Summary Table of contents Strategic Progress Financial Results AppendixConsolidated Guidance
Page 20
20 Fiscal Year 2027 Q1 Consolidated Financial Results 1 The amount after deducting “Other income” and “Other expenses” from operating profit. 2 Profit attributable to owners of parent (Billions of yen, except EPS and adjusted EPS) FY26 Q1 FY27 Q1 YoY After FX adjustment Revenue 206.5 240.4 +16% +5% Cost of sales 71.4 83.6 +17% +5% % of revenue 34.6% 34.8% +0.2pp 0.0pp SG&A expenses 122.2 125.0 +2% -6% % of revenue 59.2% 52.0% -7.2pp -6.3pp Equity method 0.2 -1.1 - - Other income and expenses 3.4 -1.7 - - Operating profit 16.6 29.0 +74% +48% % of revenue 8.0% 12.0% +4.0pp +3.3pp Adjusted operatingprofit1 13.2 30.7 +133% +98% % of revenue 6.4% 12.8% +6.4pp +5.7pp Profit before tax 16.9 27.6 +63% % of revenue 8.2% 11.5% +3.3pp Profit2 9.0 19.1 +112% EPS ¥8 ¥18 +123% Adjusted EPS ¥9 ¥20 +130% Executive Summary Table of contents Strategic Progress Financial Results AppendixConsolidated Guidance
Page 21
21 Fiscal Year 2027 Q1 Results by Business Segment (Billions of yen) FY26 Q1 FY27 Q1 YoY After FX adjustment GIS Revenue 139.0 168.4 +21% +10% Operating profit 18.1 38.6 +113% +84% % of revenue 13.0% 22.9% +9.9pp +8.9pp Adjusted operatingprofit1 20.1 39.3 +95% +69% % of revenue 14.5% 23.3% +8.9pp +7.9pp SIS Revenue 67.4 71.9 +7% -4% Operating profit (loss) -1.9 -2.4 - - % of revenue - - - - Adjusted operatingprofit1 -1.3 -2.1 - - % of revenue - - - - Corporate and Elimination2 Revenue 0.1 0 - - Operating profit (loss) 0.3 -7.3 - - Consolidated Total Revenue 206.5 240.4 +16% +5% Operating profit 16.6 29.0 +74% +48% % of revenue 8.0% 12.0% +4.0pp +3.3pp Adjusted operatingprofit1 13.2 30.7 +133% +98% % of revenue 6.4% 12.8% +6.4pp +5.7pp 1 The amount after deducting “Other income” and “Other expenses” from operating profit. 2 From FY2027, research and development and exploration activities related to new businesses no longer meet the definition of a business segment, amounts previously reported under “Other” are now reported under “Corporate and Elimination.” Accordingly, we restated figures for FY26 Q1 to reflect the changes in categorization. Executive Summary Table of contents Strategic Progress Financial Results AppendixConsolidated Guidance
Page 22
22 Factors that Affected Consolidated Adjusted Operating Profit in Fiscal Year 2027 Q1 13.2 30.7 Change in SG&A expenses +7.3 Change in sales +7.1 Change in cost of sales -0.2 Impact of foreign exchange, etc.* +3.3 FY26 Q1 Adjusted operating profit FY27 Q1 Adjusted operating profit (Billions of yen) * Equity Method is included. ▪ GIS: Increased by strong performance in North America, Europe and APAC ▪ SIS: Decreased due mainly to FDA-related import alerts and ship-holds of certain products ▪ Foreign exchange impact of elimination of unrealized gains on inventories: Approx. -¥2.4 billion Including the following ▪ Revenue decrease due to FDA-related import alerts and voluntary ship-holds: Approx. -¥13 billion ▪ Decreased due mainly to lower R&D and personnel expenses Executive Summary Table of contents Strategic Progress Financial Results AppendixConsolidated Guidance
Page 23
23 Key Product Catalysts: Gastrointestinal Solutions Division (As of August 7, 2026) Key products launched in FY2026 Key products launched and scheduled for launch in FY2027 Key products scheduled for launch from FY2028 onward GI Endoscopy ▪ EVIS X1 EDOF Video Gastroscope (US, China) ▪ EVIS X1 EDOF Video Colonoscope (US) ▪ OLYSENSE1 CAD/AI (US, EU) ▪ EU-ME3, Endoscopic Ultrasound Processor (US, China) GI EndoTherapy ▪ Retentia, Hemostasis Clip (EU, APAC) ▪ SecureFlex, EUS Needle (US, EU, Japan, APAC) ▪ EndoCuff Vision, Colonoscope distal end attachment (Japan) ▪ Foreign Body Retrieval Net (EU) ▪ Electrosurgical Snare (EU) ▪ VIABIL Biliary Metallic Stent (US) GI Endoscopy ▪ EVIS X1 EDOF Video Colonoscope (China) ▪ EVIS X1 scopes (US, EU, Japan, APAC) ▪ OLYSENSE Asset Care (EU) ▪ OLYSENSE Computer-Aided Metrics (EU) ▪ New EUS scopes (EU, Japan, APAC) ▪ Single-use duodenoscope (US, Japan) ▪ Aplio i800 EUS, diagnostic ultrasound system for EUS (US) GI EndoTherapy ▪ Retentia, Hemostasis Clip (China) ▪ VIABIL Biliary Metallic Stent (EU, APAC) GI Endoscopy ▪ EVIS X1 scopes ▪ New EUS scopes (US) ▪ OLYSENSE CAD/AI (APAC) ▪ OLYSENSE Report (EU) ▪ OLYSENSE Computer-Aided Metrics (US) ▪ OLYSENSE Insights ▪ Single-use duodenoscope (EU, APAC) GI EndoTherapy ▪ EndoClot, Hemostasis Solution (China, APAC) ▪ SecureFlex, EUS Needle (China) ▪ New Hemostasis Clip ▪ Plastic stent 1 OLYSENSE is a trademark of Olympus Corporation and/or its affiliated entities. All trademarks, logos and brand names are the property of their respective owners. Note: Products shown may not be available in all countries within the specified region. Growth drivers now GI Endoscopy ▪ EVIS X1 system and scopes ▪ EVIS EXERA III system and scopes ▪ EVIS LUCERA ELITE system and scopes ▪ EU-ME3, Endoscopic Ultrasound Processor ▪ Aplio i800 EUS, diagnostic ultrasound system for EUS GI EndoTherapy ▪ ERCP (Guidwires) ▪ ESD&EMR (ESD Knives) ▪ Sampling (Snares, Biopsy Forceps) ▪ Hemostasis (Hemostasis Clips, Hemostasis Solution) ▪ EUS (EUS Needles) EVIS X1 system EU-ME3 Guidewires ESD Knives Aplio i800 EUS Executive Summary Table of contents Strategic Progress Financial Results AppendixConsolidated Guidance
Page 24
24 Key Product Catalysts: Surgical and Interventional Solutions Division (As of August 7, 2026) 24 Key products launched in FY2026 Key products launched and scheduled for launch in FY2027 Key products scheduled for launch from FY2028 onward Urology ▪ Single-use ureteroscope & cystoscope (US, EU, APAC) ▪ SOLTIVE SuperPulsed Laser System for stone + soft tissue (Japan) ▪ VISERA S (US) ▪ OES ELITE Cystoscope (EU, APAC) Respiratory ▪ Peripheral EBUS scope (EU, Japan, APAC) ▪ EU-ME3, Endoscopic Ultrasound Processor (US, China) ▪ Single-use Bronchoscope (EU) Surgical Endoscopy ▪ VISERA ELITE III (US, China) Urology ▪ Single-use ureteroscope & cystoscope (Japan) ▪ 4K Camera Head (US, China) ▪ OES ELITE Cystoscope (US, Japan) ▪ Laser system (US, EU) ▪ BioProtect Balloon Spacer (US) Respiratory ▪ EVIS X1 bronchoscope (US) ▪ Peripheral EBUS scope (US) Surgical Endoscopy ▪ ENDOEYE Video laparoscope (US, Europe, Japan, APAC) Urology ▪ Laser system ▪ VISERA S (China) ▪ OES ELITE Cystoscope (China) Respiratory ▪ EVIS X1 bronchoscope (China) ▪ Peripheral EBUS scope (China) Surgical Endoscopy ▪ New generation surgical endoscopy system Growth drivers now Urology ▪ Resection electrodes with ESG-410 ▪ SOLTIVE SuperPulsed Laser System for stone + soft tissue Respiratory ▪ EVIS X1 bronchoscope ▪ Single-use bronchoscope ▪ Bronchoscope, EBUS scope ▪ EBUS-TBNA needles ▪ Spiration Valve System ▪ EU-ME3, Endoscopic Ultrasound Processor Surgical Endoscopy ▪ VISERA ELITE III VISERA ELITE III SOLTIVE SuperPulsed Laser System Resection electrodes with ESG-410 EVIS X1 bronchoscope EBUS-TBNA needles Note: Products shown may not be available in all countries within the specified region. Executive Summary Table of contents Strategic Progress Financial Results AppendixConsolidated Guidance
Page 25
25 Fiscal Year 2027 Q1 Consolidated Adjusted Operating Profit (Billions of yen) FY26 Q1 FY27 Q1 Operating profit 16.6 29.0 1. Adjusted items: Other income 7.0 1.1 Major items ▪ Consideration based on agreement regarding license usage rights, etc. with Evident 6.0 (Elimination and Corporate) 2. Adjusted items: Other expenses -3.6 -2.8 Major items ▪ Expenses related to quality and regulatory transformation project “Elevate” -2.4 (GIS, SIS) Adjusted operating profit 13.2 30.7 Adjusted operating profit is the amount after deducting “Other income” and “Other expenses” from operating profit. Executive Summary Table of contents Strategic Progress Financial Results AppendixConsolidated Guidance
Page 26
26 Consolidated Statement of Financial Position 1 Total assets decreased due mainly to a decrease in cash and cash equivalents resulting from shareholder returns and BioProtect acquisition, while goodwill related to the BioProtect acquisition increased. Liabilities increased due mainly to short- and long-term funding through Bonds and borrowings (¥78.0 billion). Equity decreased due mainly to share repurchases and dividend payments. (Billions of yen) End of Mar. 2026 End of Jun. 2026 Change End of Mar. 2026 End of Jun. 2026 Change Current assets 706.3 637.5 -68.8 Current liabilities 436.9 467.4 +30.5 Cash and cash equivalents 188.0 118.5 -69.5 Trade and other payables 80.6 61.7 -19.0 Bonds and borrowings 79.9 139.1 +59.3Trade and other receivables 236.8 210.3 -26.5 Inventories 207.1 221.3 +14.2 Other current liabilities etc.1 276.4 266.6 -9.8 Non-current assets 830.9 889.0 +58.1 Non-current liabilities 288.2 311.2 +22.9 Property, plant and equipment 287.2 297.7 +10.5 Bonds and borrowings 159.7 179.8 +20.1 Intangible assets 101.0 103.3 +2.3 Equity 812.0 747.9 -64.1 Goodwill 194.2 240.1 +45.9 (Equity ratio) 52.8% 49.0% -3.8pp Total assets 1,537.2 1,526.5 -10.7 Total liabilities and equity 1,537.2 1,526.5 -10.7 1 1 It includes other financial liabilities, income taxes payable, provisions, and other current liabilities, which are items on the consolidated statements of financial position. 1 1 2 2 3 2 3 Executive Summary Table of contents Strategic Progress Financial Results AppendixConsolidated Guidance
Page 27
27 Consolidated Cash Flows Major adjusted items for FY27 Q1 Operating CF: Expenditures associated with implementing initiatives to transform organization globally and optimize headcount -¥13.3 billion Investing CF: Acquisition of BioProtect Ltd. and investment in Swan Endosurgical, Inc. etc. -¥45.9 billion (Billions of yen) FY26 Q1 FY27 Q1 Change Profit before tax 16.9 27.6 +10.7 CF from operating activities (Operating CF) -15.2 14.3 +29.5 CF from investing activities (Investing CF) -17.5 -64.2 -46.7 Free cash flow (FCF) -32.7 -49.9 -17.2 Adjusted Free cash flow (Adjusted FCF) -17.5 9.2 +26.7 CF from financing activities (Financing CF) 22.5 -21.0 -43.4 Cash and cash equivalents at end of period 241.2 118.5 -122.7 FCF: Negative ¥49.9 billion due mainly to BioProtect acquisition, despite an increase in profit before tax and lower corporate income tax payments.Adjusted FCF1 was positive ¥9.2 billion. Financing CF: Negative ¥21.0 billion, as share repurchases and dividend payments were partially offset by short-term and long-term funding through Bonds and borrowings. 1 2 2 1 Adjusted for extraordinary factors such as “Cash inflows and outflows of other income and expenses”, “M&A-related expenditure”, and “Business restructuring-related expenditure”. Major adjusted items for FY26 Q1 Operating CF: Tax payment related to the transfer of Scientific Solutions Business (Overseas) -¥14.7 billion 1 Executive Summary Table of contents Strategic Progress Financial Results AppendixConsolidated Guidance
Page 28
28 Fiscal Year 2027 Consolidated Guidance 1 The amount after deducting “Other income” and “Other expenses” from operating profit. 2 Profit attributable to owners of parent (Billions of yen, Except EPS and Adjusted EPS) FY26 Full-year FY27 Guidance vs FY26 After FX adjustment Revenue 1,010.7 1,055.0 to 1,076.0 +4.4% to +6.5% +1.5% to +3.5% Cost of sales 356.6 367.5 to 369.0 +3.1% to +3.5% +2.7% to +3.1% % of revenue 35.3% 34.3% to 34.8% -1.0pp to -0.4pp -0.1pp to +0.4pp SG&A expenses 507.1 519.5 to 520.0 +2.4% to +2.5% -0.1% to 0% % of revenue 50.2% 48.3% to 49.2% -1.8pp to -0.9pp -1.7pp to -0.8pp Other income and expenses etc. -49.9 -31.5 - - Operating profit 97.1 136.5 to 155.5 +40.6% to +60.1% +23.3% to +42.6% % of revenue 9.6% 12.9% to 14.5% +3.3pp to +4.8pp +2.1pp to +3.6pp Adjusted operatingprofit1 143.3 160.5 to 179.5 +12.0% to +25.3% +1.4% to +14.5% % of revenue 14.2% 15.2% to 16.7% +1.0pp to +2.5pp 0pp to +1.5pp Profit2 68.2 95.5 to 109.0 +40.1% to +59.9% EPS ¥61 ¥90 to ¥102 +46% to +67% Adjusted EPS ¥92 ¥106 to ¥119 +15% to +29% Dividend guidance for FY27 Year-end dividend of ¥30 per share Executive Summary Table of contents Strategic Progress Financial Results AppendixConsolidated Guidance
Page 29
29 Fiscal Year 2027 Guidance by Business Segment 1 The amount after deducting “Other income” and “Other expenses” from operating profit. 2 From FY2027, research and development and exploration activities related to new businesses no longer meet the definition of a business segment, amounts previously reported under “Other” are now reported under “Corporate and Elimination.” Accordingly, we restated figures for FY26 full-year to reflect the changes in categorization. (Billions of yen) FY26 Full-year FY27 Guidance vs FY26 After FX adjustment GIS Revenue 697.4 744.0 to 749.0 +6.7% to +7.4% +3.7% to +4.5% Operating profit 136.4 173.5 to 180.0 +27.2% to +32.0% +17.4% to +22.2% % of revenue 19.6% 23.3% to 24.0% +3.8pp to +4.5pp +2.6pp to +3.3pp Adjusted operatingprofit1 164.4 181.5 to 188.0 +10.4% to +14.4% +2.2% to +6.2% % of revenue 23.6% 24.4% to 25.1% +0.8pp to +1.5pp -0.3pp to +0.4pp SIS Revenue 313.1 311.0 to 327.0 -0.7% to +4.4% -3.5% to +1.5% Operating profit (loss) -15.0 -2.5 to 10.0 - - % of revenue - - - - Adjusted operatingprofit1 0.8 5.0 to 17.5 +517.4% to +2,061.1% +196.4% to +1,715.3% % of revenue 0.3% 1.6% to 5.4% +1.3pp to +5.1pp +0.5pp to +4.4pp Corporate and Elimination2 Revenue 0.2 - - - Operating profit (loss) -24.3 -34.5 - - Consolidated Total Revenue 1,010.7 1,055.0 to 1,076.0 +4.4% to +6.5% +1.5% to +3.5% Operating profit 97.1 136.5 to 155.5 +40.6% to +60.1% +23.3% to +42.6% % of revenue 9.6% 12.9% to 14.5% +3.3pp to +4.8pp +2.1pp to +3.6pp Adjusted operatingprofit1 143.3 160.5 to 179.5 +12.0% to +25.3% +1.4% to +14.5% % of revenue 14.2% 15.2% to 16.7% +1.0pp to +2.5pp 0pp to +1.5pp Executive Summary Table of contents Strategic Progress Financial Results AppendixConsolidated Guidance
Page 30
30 Expenditures: Fiscal Year 2027 Q1 Actuals and Fiscal Year 2027 Guidance 27.9 21.7 16.2 25.5 28.0 17.3 119.0 95.0 68.0 R&D expenditures Capital expenditures Depreciation and amortization FY26 Q1 FY27 Q1 FY27 Guidance(Billions of yen) (Billions of yen) FY26 Q1 FY27 Q1 FY27 Guidance R&D expenditures1 (a) 27.9 25.5 119.0 Capitalization of R&D expenditures (b) 4.2 4.6 25.0 R&D expenses in P/L (a-b) 23.7 20.9 94.0 (Billions of yen) FY26 Q1 FY27 Q1 Amortization 2.0 2.1 End of Mar. 2026 End of Jun. 2026 R&D assets 71.7 74.7 1 Capitalization of R&D expenditures (b) is included in R&D expenditures. 2 Capitalization of R&D expenditures (b) is included in capital expenditures. In addition, the Olympus Group has adopted IFRS #16 "Leases" from FY20, and right-of use assets below are included in capital expenditures. (FY26 Q1: ¥4.1 billion, FY27 Q1: ¥8.3 billion, FY27 Guidance: ¥13.0 billion)1 2 Executive Summary Table of contents Strategic Progress Financial Results AppendixConsolidated Guidance
Page 31
31 Foreign Exchange and Sensitivity Forex sensitivity (annualized impact) (Billions of yen) Revenue Operating profit U.S. dollar (per yen) 2.9 0.5 Euro (per yen) 1.7 0.5 CNY (per yen) 3.9 1.7 * Amounts in the above table are related to the continuing operations only. Forex sensitivity (annualized impact) is calculated based on the FY26 Q4 results. Foreign exchange rate (Yen) FY26 Q1 FY27 Q1 FY27 Guidance Yen/U.S.dollar 144.59 159.49 155 Yen/Euro 163.80 185.39 181 Yen/CNY 19.99 23.43 22.5 Executive Summary Table of contents Strategic Progress Financial Results AppendixConsolidated Guidance
Page 32
32 Acronyms Acronyms Term APAC Asia Pacific BPH Benign Prostatic Hyperplasia EBUS-TBNA Endobronchial Ultrasound-guided Transbronchial Fine Needle Aspiration EMR Endoscopic Mucosal Resection ERCP Endoscopic Retrograde Cholangio Pancreatography ESD Endoscopic Submucosal Dissection EUS Endoscopic Ultrasound Executive Summary Table of contents Strategic Progress Financial Results AppendixConsolidated Guidance